Nvidia Corp vs uniQure N.V. Ordinary Shares — how do they compare? Nvidia Corp trades at $217.84 (market cap $5.52T), while uniQure N.V. Ordinary Shares trades at $20.67 (market cap $1.48B). The key difference: Nvidia Corp is far larger — about 3729.7× uniQure N.V. Ordinary Shares's market cap, and Nvidia Corp pays a 0.44% dividend while uniQure N.V. Ordinary Shares pays none. Which is the better fit depends on your goals — on Pluang, investors hold Nvidia Corp for 116 Days and uniQure N.V. Ordinary Shares for 0 Days on average.
| NVDA | QURE | |
|---|---|---|
Market Cap | $5.52T | $1.48B |
Volume | 84,036,941 | 2,488,780 |
Sector | Technology | Health |
52-Week High | $239.27 | $70.59 |
52-Week Low | $165.17 | $9.03 |
Typical Hold Time | 116 Days | 0 Days |
Enterprise Value | $5.49T | $728.62M |
Dividend Yield | 0.44% | — |
Signals from Pluang's Aura AI — not financial advice
NVIDIA (NVDA) trades at $228.52, up 0.97% with strong fundamental performance including 55.84% net profit margin and consistent earnings beats. The stock shows bullish technical signals with support at $225 and resistance at $228. Revenue growth accelerated to $130.5B in 2025, while analyst consensus remains strongly bullish with a $339.17 price target representing 48% upside potential.
NVIDIA's AI leadership and expanding market position support continued growth, though valuation multiples remain elevated. Key risks include increased competition and potential market saturation in AI chips. The company's strong cash flow generation and institutional support provide fundamental backing for long-term investors despite near-term volatility concerns.
No Aura AI signal available yet.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
NVIDIA Corporation designs, develops, and markets three dimensional (3D) graphics processors and related software. The Company offers products that provides interactive 3D graphics to the mainstream personal computer market.
Read more on NVDA →uniQure N.V. is a biotechnology company that develops gene therapies for rare and severe genetic diseases, marketing HEMGENIX for hemophilia B and advancing its AAV-based miQURE platform in programs such as AMT-130 for Huntington's disease.
Read more on QURE →